Previous 10 | Next 10 |
The following slide deck was published by Horizon Pharma plc in conjunction with their 2019 Q1 earnings Read more ...
Horizon Pharma ( HZNP ) Q1 results : Revenues: $280.4M (+25.2%); Orphan sales: $114.2M (-0.4%); Rheumatology sales: $71.7M (+24.7%). More news on: Horizon Pharma plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Horizon Pharma (NASDAQ: HZNP ): Q1 Non-GAAP EPS of $0.30 beats by $0.18 ; GAAP EPS of -$0.19. More news on: Horizon Pharma plc, Earnings news and commentary, Healthcare stocks news, Read more ...
-- First-Quarter 2019 Net Sales of $280.4 Million Increased 25 Percent; First-Quarter 2019 GAAP Net Loss of $32.9 Million; Adjusted EBITDA of $88.4 Million -- -- Quarterly Orphan and Rheumatology Segment Net Sales Increased 8 Percent to $185.9 Million -- -- Increasing Full-Year...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2019 of inducement restricted stock units for an aggregate of 53,008 ordinary shares to 31 new employees. The restricted stock units vest over th...
Portola Pharmaceuticals ( PTLA ) - The company announced that the European Commission granted conditional Marketing Authorization for Ondexxya (andexanet alfa) to be used in adult patients treated with the Factor Xa inhibitor apixaban or rivaroxaban when reversal of anticoagulation is needed...
Horizon Pharma ( HZNP ) reported overwhelmingly positive phase 3 results of teprotumumab in patients with thyroid eye disease (‘TED’) in the first quarter. The results exceeded those observed in the phase 2 study on the primary endpoint and all the secondary endpoints have be...
-- Efficacy Demonstrated Across Measures Not Addressed by Current Therapies -- -- New Data at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress Demonstrates Significant Proptosis Reduction and Improvement in Overall Response Rate -- ...
Data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significa...
Noteworthy events during the week of April 21 - 27 for healthcare investors. More news on: Galmed Pharmaceuticals Ltd., Horizon Pharma plc, Concert Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...